Therapy Areas: Respiratory
Vicore Pharma starts ATRAG C106 first-in-human trial
17 June 2022 -

Vicore Pharma Holding AB (STO:VICO), a Sweden-based clinical-stage pharmaceutical company, announced on Thursday the commencement of a first-in-human trial with the novel ATRAG C106.

Vicore expects this trial to read out during the third quarter of 2023.

The product is first of the four advanced candidate drugs from the VP03 programme to enter clinical trials. It is orally available with target engagement and anti-fibrotic impact in human fibrotic lung and kidney tissue at clinically relevant concentrations. It is likely to have patent protection until around 2040.

This first-in-human trial is a double-blind, placebo-controlled, randomised, single-centre trial to assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of the product. The trial is likely to include around 72 healthy volunteers and will be conducted in Uppsala, Sweden.



Related Headlines